CClinicalTrials.gg
WithdrawnNCT05906979Updated Mar 27, 2026

Digital Human-Based Brief Interventions for Harmful Alcohol Use: The PAHOLA Project

An interventional study of PAHOLA (digital health assistant) and Standard information on alcohol use and health in Alcohol Drinking and Alcoholism, sponsored by Centre for Addiction and Mental Health. Withdrawn. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Centre for Addiction and Mental Health · Not applicable, Interventional, and Treatment

Why this study was withdrawn
The tool to be evaluated is no longer provided by the WHO
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Alcohol use disorders are among the most prevalent mental disorders in Canada; however, due to numerous barriers, including fear of treatment, privacy concerns, stigma, time conflicts, and lack of availability of treatment, less than 10% of people with alcohol dependence receive treatment. Accordingly, there is a need to expand treatment coverage for alcohol use disorders, especially for populations which face barriers to receiving treatment.

The objective of this proposed project is to develop a digital health worker, named PAHOLA, which can effectively deliver interventions to people who would not otherwise receive such treatment. To achieve this objective, the following research aims will be addressed:

  1. To develop a digital human-based intervention that can initiate change processes and reduce alcohol use by applying the principles of motivational interviewing (MI) and cognitive behavioural therapy (CBT) in a credible manner.
  2. To assess the impact of the virtual care provided by PAHOLA on health outcomes using a randomized controlled study design (RCT) to assess potential effect sizes for a larger future RCT.

If successful, the PAHOLA project has the potential to transform our ability to prevent alcohol-attributable harms in Canada by promoting health, health equity, and well-being, especially among those people who do not normally receive treatment for harmful alcohol use.

Read the detailed description

Alcohol use disorders are among the most prevalent mental disorders in Canada; however, due to numerous barriers, including fear of treatment, privacy concerns, stigma, time conflicts, and lack of availability of treatment, less than 10% of people with alcohol dependence receive treatment. Accordingly, there is a need to expand treatment coverage for alcohol use disorders, especially for populations which face barriers to receiving treatment.

.

The objective of this proposed project is to tailor PAHOLA into a digital health worker which can effectively deliver BIs to people who would not otherwise receive such treatment. To achieve this objective, the following research aims will be addressed:

3. To develop a digital human-based intervention that can initiate change processes and reduce alcohol use by applying the principles of motivational interviewing (MI) and cognitive behavioural therapy (CBT) in a credible manner.

4. To assess the impact of the virtual care provided by PAHOLA on health outcomes using a randomized controlled study design (RCT) to assess potential effect sizes for a larger future RCT.

To address these objectives, the study will employ the following research strategy

This project will build upon the PAHOLA digital human prototype which was developed by Soul Machines, the Pan American Health Organization (PAHO), and Rooftop to provide information on alcohol risks and harms. This project will develop PAHOLA to intervene in cases of hazardous and harmful alcohol use, and will take place in the following three phases:

Phase 1 - development of the intervention dialogue flow program. PAHOLA will (i) screen for harmful alcohol use using the AUDIT, and (ii) deliver Brief Intervention (BIs). The BIs will be based primarily on two evidence-based approaches that are used to effectively treat alcohol misuse, namely MI and CBT. Dialogue will be constructed in alignment with FRAMES - Feedback, Responsibility, Advice, Menu of options, Empathy, and Self efficacy (confidence for change),and OARS - (Open ended questions, Affirmation, Reflective listening, and Summarizing).

Phase 2 - a two-day virtual meeting of researchers, health care providers, and people with lived experience. A virtual meeting of a total of 30 experts will be held to comment upon and further develop PAHOLA. Meeting participants will formulate a series of evidence-based recommendations regarding how to improve: 1) the affinity and trustworthiness of PAHOLA, 2) the dialogue flow for BIs, and 3) the specific dialogue flows for men and women.

Phase 3 - a pilot randomized controlled trial (RCT) of the PAHOLA intervention program. To assess PAHOLA as a potential intervention for treating harmful alcohol use, a pilot RCT will be performed where the first group will receive a BI, the second group will receive a text-only version of PAHO's BI, and the third group will receive information from PAHOLA about the risks of alcohol use. A total of 180 adults (18 years of age and older) with hazardous and harmful alcohol use will be recruited via online advertisements and databases of individuals interested in participating in research studies.

02

Conditions studied

  • Alcohol Drinking
  • Alcoholism
03

In context

Alcohol Drinking

925 studies on the registry are indexed under Alcohol Drinking; 172 are open to participants now.

Browse Alcohol Drinking studies →

Lead sponsor

Centre for Addiction and Mental Health is the lead sponsor of 327 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Current drinkers 18 years of age and older who score 7 to 23 on the Alcohol Use Disorders Identification Test
  2. Use of medication to treat harmful alcohol use will be allowed provided that the dose has been stable for 8 weeks
  3. Availability of a computer with a connection to the internet and a camera and microphone

Exclusion criteria

Exclusion Criteria:

  1. A history of drug use disorders (other than alcohol) in the last two years (except tobacco use disorder)
  2. Dose changes of concomitant medications will not be permitted during the study period
  3. Pregnant or lactating women, and women of childbearing potential who are not using medically accepted forms of contraception, or women who are planning on becoming pregnant during the study time frame
  4. People who are currently reciving psychological treatment for alcohol use disorders
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Digital intervention

    Participants will interact with PAHOLA the digital assistant of the Pan American Health Organization.

    Other: PAHOLA (digital health assistant)

  • Experimental
    Digital intervention (text only)

    Participants will interact with PAHOLA (text only version) the digital assistant of the Pan American Health Organization.

    Other: PAHOLA (digital health assistant)

  • Other
    Information on alcohol use and risk

    A PDF containing standard information on alcohol use and risk from the Pan American Health Organization.

    Other: Standard information on alcohol use and health

Interventions

  • OtherPAHOLA (digital health assistant)

    Pahola is the Pan American Health Organization's new digital health specialist on alcohol use. Programmed with the latest information and research, she can help you make healthier decisions related to your alcohol consumption. Pahola is free to use and can easily be accessed from the privacy of your own home by making use of the online app.

  • OtherStandard information on alcohol use and health

    A brochure on alcohol use and health as produced by the Pan American Health Organization will be provided to participants.

06

What researchers measure

Primary outcomes

  1. Changes in alcohol use quantity

    Alcohol use quantity (measured in average grams per day in the past week)

    Time frame: 1 month

  2. Changes in alcohol use quantity

    Alcohol use quantity (measured in average grams per day in the past week)

    Time frame: 3 months

  3. Changes in alcohol use quantity

    Alcohol use quantity (measured in average grams per day in the past week)

    Time frame: 6 months

  4. Changes in alcohol use frequency

    Alcohol use frequency (measured in drinking days in the past week)

    Time frame: 1 month

  5. Changes in alcohol use frequency

    Alcohol use frequency (measured in drinking days in the past week)

    Time frame: 3 months

  6. Changes in alcohol use frequency

    Alcohol use frequency (measured in drinking days in the past week)

    Time frame: 6 months

  7. Changes in Alcohol Use Disorders Identification Test (AUDIT) items 5 to 10 scores

    Alcohol Use Disorders Identification Test (AUDIT) items 5 to 10 scores; Scale (0 to 15); Higher scores indicate harmful alcohol use.

    Time frame: 1 month

  8. Changes in Alcohol Use Disorders Identification Test (AUDIT) items 5 to 10 scores

    Alcohol Use Disorders Identification Test (AUDIT) items 5 to 10 scores; Scale (0 to 15); Higher scores indicate harmful alcohol use.

    Time frame: 3 months

  9. Changes in Alcohol Use Disorders Identification Test (AUDIT) items 5 to 10 scores

    Alcohol Use Disorders Identification Test (AUDIT) items 5 to 10 scores; Scale (0 to 15); Higher scores indicate harmful alcohol use.

    Time frame: 6 months

Secondary outcomes

  1. Changes in anxiety

    Hamilton Anxiety Rating Scale (HAM-A) 36; Scale range: 0-56; Higher scores indicate worse anxiety

    Time frame: 1 months

  2. Changes in anxiety

    Hamilton Anxiety Rating Scale (HAM-A) 36; Scale range: 0-56; Higher scores indicate worse anxiety

    Time frame: 3 months

  3. Changes in anxiety

    Hamilton Anxiety Rating Scale (HAM-A) 36; Scale range: 0-56; Higher scores indicate worse anxiety

    Time frame: 6 months

  4. Changes in depression

    Patient Depression Questionnaire - 9 item version; Scale range: 0 to 27; Higher scores indicate worse depression

    Time frame: 1 months

  5. Changes in depression

    Patient Depression Questionnaire - 9 item version; Scale range: 0 to 27; Higher scores indicate worse depression

    Time frame: 3 months

  6. Changes in depression

    Patient Depression Questionnaire - 9 item version; Scale range: 0 to 27; Higher scores indicate worse depression

    Time frame: 6 months

  7. Changes in quality of life

    Short Form Health Survey-12 item (SF-12); Scale range: 0 to 100; Higher scores indicating better physical and mental health functioning.

    Time frame: 1 month

  8. Changes in quality of life

    Short Form Health Survey-12 item (SF-12); Scale range: 0 to 100; Higher scores indicating better physical and mental health functioning.

    Time frame: 3 months

  9. Changes in quality of life

    Short Form Health Survey-12 item (SF-12); Scale range: 0 to 100; Higher scores indicating better physical and mental health functioning.

    Time frame: 6 months

  10. Packs of cigarettes smoked in the past week

    Packs of cigarettes smoked in the past week

    Time frame: 1 month

  11. Packs of cigarettes smoked in the past week

    Packs of cigarettes smoked in the past week

    Time frame: 3 months

  12. Packs of cigarettes smoked in the past week

    Packs of cigarettes smoked in the past week

    Time frame: 6 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05906979
Lead sponsor
Centre for Addiction and Mental Health
Collaborators
Canadian Institutes of Health Research (CIHR), Pan American Health Organization
Responsible party
Jurgen Rehm (Senior Scientist, Centre for Addiction and Mental Health) — Principal investigator
First posted
Jun 18, 2023
Start date
May 1, 2022 (estimated)
Primary completion
May 1, 2022 (estimated)
Completion
May 1, 2022 (estimated)
Last update
Mar 27, 2026

Study contacts

Kevin Shield
principal investigator · Centre for Addiction and Mental Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion